API Ibrutinib Raw Material Powder Ibrutinib Pharmaceutical Intermediate Ibrutinib
Product Description
Product Details
| Product Name |
Ibrutinib |
| Appearance |
White to off-white powder |
| CAS No. |
936563-96-1 |
| MF |
C25H24N6O2 |
| MW |
440.507 |
Ibrutinib is a white or white solid, soluble in dimethyl sulfoxide, soluble in methanol, insoluble in water; It is a small molecule BTK inhibitor that can covalently bind to cysteine residues in the active center of BTK, thereby inhibiting its activity. According to lu for his can inhibit malignant B lymphocyte proliferation and survival in the body.
Application & Function
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL are B-cell non-Hodgkin's lymphomas, which are refractory and easy to relapse. Commonly used chemotherapy and immunotherapy are not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can be targeted to bind with BTK necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells; and it is absorbed rapidly after oral administration, 1~ The maximum blood drug concentration reached 2 hours, and the adverse reaction is classified as 1 or 2, which will become a new choice for the treatment of CLL and MCL.
Specification
Audited Supplier 
){kind=link}
){kind=link}